Advances in therapy
Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis.
Elena Cortés-Vicente, Antonio Guerrero, Carmina Díaz, Eva Martínez, Francisco J Toja-Camba, María R Abad, José M Serra, Jose L Trillo, Celia Martín Machín, Alicia Gil
Published: 202610.1007/s12325-026-03490-x
Abstract
INTRODUCTION: Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune neuromuscular disorder that currently lacks a curative treatment. Efgartigimod alfa is the first human IgG1 Fc fragment approved in Spain for the management of this condi…
Preview only. Read the full abstract at the source